Compounds > 2-aminoadamantane
Page last updated: 2024-11-05

2-aminoadamantane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-aminoadamantane: inhibits lymphocyte proliferation; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25332
CHEMBL ID1170792
SCHEMBL ID75970
SCHEMBL ID4657616
SCHEMBL ID4688717
SCHEMBL ID12876277
SCHEMBL ID13243472
SCHEMBL ID2400612
SCHEMBL ID15088151
SCHEMBL ID7436572
SCHEMBL ID17203865
MeSH IDM0191057

Synonyms (43)

Synonym
HMS1787I03
LS-13853
2-adamantanamine
tricyclo[3.3.1.13,7]decan-2-amine
jp 60
nsc-127842
nsc127842
2-aminoadamantane
2-adamantylamine
13074-39-0
tricyclo(3.3.1.1(3,7))decan-2-amine
OPREA1_605085
tricyclo[3.3.1.1~3,7~]decan-2-amine
STK099532
AKOS000113996
CHEMBL1170792 ,
adamantan-2-amine
AKOS001033453
A806142
nsc 127842
tricyclo(3.3.1.13,7)decan-2-amine
SCHEMBL75970
ac17
AKOS016037117
adamantan-2-ylamine
2-amino-adamantane
SCHEMBL4657616
SCHEMBL4688717
SCHEMBL12876277
SCHEMBL13243472
SCHEMBL2400612
SCHEMBL15088151
SCHEMBL7436572
DTXSID90156707
SCHEMBL17203865
bdbm50482329
FT-0728401
EN300-57378
CS-0094367
D94469
SY180443
mfcd00078225
PD096138
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Matrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))Kd2.36000.01600.89872.3600AID489224
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
uncoating of virusMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
proton transmembrane transporter activityMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneMatrix protein 2Influenza A virus (A/Puerto Rico/8/1934(H1N1))
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay IDTitleYearJournalArticle
AID1152163Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells expressing M2 V27T/S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1438084Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152166Antiviral activity against Influenza A virus A/Victoria/3/75(H3N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1152164Antiviral activity against Influenza A virus A/WS/33(H1N1) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1438094Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing M2 proton channel S31N mutant infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438102Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as TdeltaS values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438095Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) expressing wild-type M2 proton channel infected in MDCK cells assessed as reduction in cytopathic effect after 48 hrs by crystal violet staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438083Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152165Antiviral activity against Influenza A virus A2/Taiwan/1/64(H2N2) infected in MDCK cells expressing wild type M2 after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1152167Cytotoxicity against MDCK cells at 50 uM after 18 hrs2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1440388Toxicity in mouse2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1438101Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as deltaH values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438100Binding affinity to synthetic wild-type C-terminally amidated Influenza A virus (A/Udorn/307/72) M2 transmembrane domain (22 to 46 residues) in DPC micelles assessed as deltaG values at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438093Inhibition of Influenza A virus (A/California/07/2009(H1N1)) M2 proton channel S31N mutant expressed in HEK cells assessed as inhibition of low-pH-dependent inward proton currents at pH 5.5 in presence of CaCl2 by electrophysiology method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438105Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as TdeltaS values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1438104Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as deltaH values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152161Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells at 10 uM after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1438092Inhibition of Influenza A virus (A/California/07/2009(H1N1)) M2 proton channel S31N mutant expressed in HEK cells assessed as inhibition of low-pH-dependent inward proton currents at 10 uM and pH 5.5 measured after 3 mins in presence of CaCl2 by electroph2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152162Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells expressing M2 S31N mutant after overnight incubation by fluorescence-based miniplaque assay2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1152159Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 S31N mutant expressed in HEK cells at 100 uM after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1438103Binding affinity to synthetic Influenza A virus (A/Udorn/307/72) M2 transmembrane domain S31N mutant (22 to 46 residues) in DPC micelles assessed as deltaG values measured at pH 8 by ITC method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152160Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 S31N mutant expressed in HEK cells at 100 uM after 30 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1152158Blockade of Influenza A virus (A/England/195/2009(H1N1)) full length M2 proton channel expressed in HEK cells after 3 mins by voltage clamp technique2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID1438096Cytotoxicity against MDCK cells measured after 72 hrs et staining-based microscopic analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Binding and Proton Blockage by Amantadine Variants of the Influenza M2
AID1152183Antiviral activity against Influenza B virus B/Russia/69 infected in MDCK cells at 50 uM2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.
AID489224Binding affinity to Influenza A Weybridge(H7N7) virus Matrix protein 2 by spectrophotometry2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-docking using a pore blocking model.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's0 (0.00)29.6817
2010's11 (91.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
amantadine
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source		3.5780adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
benzbromarone
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.		3.25101-benzofurans;
aromatic ketone		uricosuric drug
broxyquinoline
broxyquinoline: structure		3.2510organohalogen compound;
quinolines
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		3.2510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
chloroxine
chloroxine : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 have been substituted by chlorine. A synthetic antibacterial prepared by chlorination of quinolin-8-ol, it is used for the treatment of dandruff and seborrhoeic dermatitis of the scalp.		3.2510monohydroxyquinoline;
organochlorine compound		antibacterial agent;
antifungal drug;
antiseborrheic
clioquinol
Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.		3.2510monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
cyclopentylamine
[no description available]		2.0510
danthron
danthron: structure. chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.		3.2510dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
hexachlorophene
Hexachlorophene: A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797). hexachlorophene : An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union.		3.2510bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		3.2510phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
rimantadine
Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.		2.7730alkylamine
benzethonium chloride
benzethonium chloride : A (synthetic) quaternary ammonium salt that is benzyldimethylamine in which the nitrogen is quaternised by a 2-{2-[p-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl group, with chloride as the counter-ion. An antiseptic and disinfectant, it is active against a broad spectrum of bacteria, fungi, moulds and viruses.		3.2510aromatic ether;
chloride salt;
quaternary ammonium salt		antibacterial agent;
antifungal agent;
antiseptic drug;
antiviral agent;
disinfectant
gentian violet
Gentian Violet: A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.. crystal violet : An organic chloride salt that is the monochloride salt of crystal violet cation. It has been used in creams for the topical treatment of bacterial and fungal infections, being effective against some Gram-positive bacteria (notably Staphylococcus species) and some pathogenic fungi (including Candida species) but use declined following reports of animal carcinogenicity. It has also been used for dying wood, silk, and paper, as well as a histological stain.		3.2510organic chloride saltanthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye
nitroxoline
nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.		3.2510C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
oseltamivir
Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.		2.1510acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.2510organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		3.2510artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
magnolol
[no description available]		3.2510biphenyls
honokiol
[no description available]		3.2510biphenyls
tetrandrine
tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity		3.2510bisbenzylisoquinoline alkaloid;
isoquinolines
prochlorperazine edisylate salt
[no description available]		3.2510
alexidine dihydrchloride
[no description available]		3.2510
dicyclomine hydrochloride
dicyclomine hydrochloride : The hydrochloride salt of dicyclomine. An anticholinergic, it is used to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.		3.2510hydrochlorideantispasmodic drug;
muscarinic antagonist
artenimol
[no description available]		3.2510
toremifene citrate
[no description available]		3.2510stilbenoidanticoronaviral agent
bromantane
bromantane: a derivative of 2-aminoadamantane; a CNS stimulant		1.9810
pterostilbene
[no description available]		3.2510diether;
methoxybenzenes;
stilbenol		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
perhexiline maleate
[no description available]		3.2510
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		3.2510antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
guttiferone e
guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source		3.2510
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		3.2510artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		3.2510biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
pyrvinium pamoate
[no description available]		3.2510naphthoic acidanticoronaviral agent
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Fungal Diseases
[description not available]		03.0610
Mycoses
Diseases caused by FUNGI.		03.0610